MedTrace Logo

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

NCT07102381 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2026-04-29

No results posted yet for this study

Summary

The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

Conditions

Interventions

DRUG

Carboplatin

Administered intravenously (IV)

DRUG

Trastuzumab

Administered intravenously (IV)

DRUG

Pertuzumab

Administered intravenously (IV)

DRUG

Zanidatamab

Administered intravenously (IV)

DRUG

Paclitaxel

Administered intravenously (IV)

DRUG

Docetaxel

Administered intravenously (IV)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-24
Primary Completion
2028-01-01
Completion
2030-08-01
FDA Drug
Yes

Countries

  • United States
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07102381 on ClinicalTrials.gov